Dr. Mallick's research focuses on the clinical application of biomarkers, particularly circulating tumor DNA (ctDNA), to guide treatment decisions in colorectal cancer. She is involved in clinical trials like the NRG-GI005 and NRG-GI008, which explore treatment escalation based on ctDNA levels in early-stage disease, with a specilization in gastrointestinal cancers, including colorectal, pancreatic, and liver cancers, as well as bone and soft tissue sarcomas
Atrayee Basu Mallick, MD
Director, Solid Tumor Division
Associate Professor
Contact Information
Honickman Center
1101 Chestnut Street
14th Floor
Philadelphia, PA 19107
Director, Solid Tumor Division
Associate Professor
RESEARCH & CLINICAL INTEREST
Education
Medical School
University of Calcutta Medical College, India
Residency
SUNY at Brooklyn NY
Montefiore Medical Center, NY
Most Recent Peer-Reviewed Publications
- PHF1::TFE3-positive fibromyxoid sarcoma? Report of 2 cases and review of 13 cases of PHF1::TFE3-positive ossifying fibromyxoid tumor in the literature
- TOMM20 as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis
- Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma
- Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy
- Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas
Board Certifications
Internal Medicine
Medical Oncology
Hematology